Anil Singhal
Directeur/Membre du Conseil chez TRISALUS LIFE SCIENCES, INC.
Fortune : 2 552 $ au 30/04/2024
Profil
Dr. Anil Singhal is an Independent Director at TriSalus Life Sciences, Inc., a President, Chief Executive Officer & Director at Trishula Therapeutics, Inc. and an Advisory Board at Accelerator Services Corp.
He is on the Board of Directors at TriSalus Life Sciences, Inc., Trishula Therapeutics, Inc. and TriSalus Operating Life Sciences, Inc. Dr. Singhal was previously employed as a President, Chief Executive Officer & Director by Adicet Therapeutics, Inc., a Vice President by AbbVie, Inc., a Vice President by Abbott, a Vice President by Xerion Pharmaceuticals AG, a Vice President by Light Sciences Oncology, Inc., a Vice President by Pacific Pharmaceuticals, Inc., and a Chief Scientific Officer by OncoResponse, Inc. He also served on the board at Nektar Therapeutics and The Biomembrane Institute.
He received his MBA from the University of Washington and a doctorate degree from Rutgers State University of New Jersey.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 03/04/2024 | 257 ( 0,00% ) | 2 552 $ | 30/04/2024 |
Postes actifs de Anil Singhal
| Sociétés | Poste | Début |
|---|---|---|
| TRISALUS LIFE SCIENCES, INC. | Directeur/Membre du Conseil | 10/08/2023 |
TriSalus Operating Life Sciences, Inc.
 TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO. | Directeur/Membre du Conseil | 16/07/2018 |
Trishula Therapeutics, Inc.
 Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | Directeur Général | 21/01/2021 |
Accelerator Services Corp
 Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Consultant / Advisor | - |
Anciens postes connus de Anil Singhal
| Sociétés | Poste | Fin |
|---|---|---|
Adicet Therapeutics, Inc.
 Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Directeur Général | 15/09/2020 |
| ABBVIE INC. | Private Equity Investor | 02/01/2017 |
| Abbott | Private Equity Investor | 30/06/2013 |
| NEKTAR THERAPEUTICS | Directeur/Membre du Conseil | 30/12/2007 |
Xerion Pharmaceuticals AG
 Xerion Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Xerion Pharmaceuticals GmbH develops antibodies and therapeutic targets. It uniquely focuses on proteins, using proprietary technologies to selectively block their function in diseased cells thereby mimicking the activity of a drug. The company is headquartered in Munich, Germany. | Private Equity Investor | 30/04/2005 |
Formation de Anil Singhal
| University of Washington | Masters Business Admin |
| Rutgers State University of New Jersey | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| NEKTAR THERAPEUTICS | Health Technology |
| ABBVIE INC. | Health Technology |
| TRISALUS LIFE SCIENCES, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Light Sciences Oncology, Inc.
 Light Sciences Oncology, Inc. Pharmaceuticals: MajorHealth Technology Light Sciences Oncology, Inc. operates as a pharmaceutical company. It develops Aptocine for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia. The company was founded in 1994 and is headquartered in Bellevue, WA. | Health Technology |
| Pacific Pharmaceuticals, Inc. | Health Technology |
Accelerator Services Corp
Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Finance |
Xerion Pharmaceuticals AG
Xerion Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Xerion Pharmaceuticals GmbH develops antibodies and therapeutic targets. It uniquely focuses on proteins, using proprietary technologies to selectively block their function in diseased cells thereby mimicking the activity of a drug. The company is headquartered in Munich, Germany. | Health Technology |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO. | Health Technology |
| The Biomembrane Institute | |
Adicet Therapeutics, Inc.
Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Health Technology |
OncoResponse, Inc.
 OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Health Technology |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | Health Technology |
| Abbott |
